A high-throughput in Vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Halvorson, Kyle G ^a,b,c   Barton, Kelly L ^a   Schroeder, Kristin ^a,b   Misuraca, Katherine L ^d   Hoeman, Christine ^a   Chung, Alex ^a   Crabtree, Donna M ^a   Cordero, Francisco J ^a   Singh, Raj ^a   Spasojevic, Ivan ^b,c   Berlow, Noah ^e   Pal, Ranadip ^e   Becher, Oren J ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY   (United States)

^e Department of Electrical and Computer Engineering   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; AURORA A KINASE; AURORA B KINASE; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; HISTONE H3; INSULIN RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE A; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; ANTINEOPLASTIC AGENT; PYRAZOLE DERIVATIVE; TRIAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SCREENING; DRUG TUMOR LEVEL; HIGH THROUGHPUT SCREENING; IC50; IN VITRO STUDY; MOUSE; MOUSE MODEL; NONHUMAN; PONTINE GLIOMA; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL TIME; ANIMAL; BRAIN STEM NEOPLASMS; C57BL MOUSE; DISEASE MODEL; GLIOMA; PATHOLOGY; SURVIVAL RATE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN STEM NEOPLASMS; DISEASE MODELS, ANIMAL; GLIOMA; HIGH-THROUGHPUT SCREENING ASSAYS; MICE; MICE, INBRED C57BL; PYRAZOLES; SURVIVAL RATE; TRIAZINES;

EID: 84924089102     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118926     Document Type: Article

References (41)

1. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. Journal of the National Cancer Institute. 2011; 103(9):714-36. Epub 2011/04/02. doi: 10.1093/jnci/djr077 PMID: 21454908; PubMed Central PMCID: PMC3086878.
2. Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, et al. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. 1999;NIH Pub. No. 99-4649.
3. Minturn JE, Fisher MJ. Gliomas in children. Current treatment options in neurology. 2013; 15(3):316-27. Epub 2013/02/27. doi: 10.1007/s11940-013-0225-x PMID: 23440592.
4. Berger MS, Edwards MS, LaMasters D, Davis RL, Wilson CB. Pediatric brain stem tumors: radiographic, pathological, and clinical correlations. Neurosurgery. 1983; 12(3):298-302. Epub 1983/03/01. PMID: 6302553.
5. Littman P, Jarrett P, Bilaniuk LT, Rorke LB, Zimmerman RA, Bruce DA, et al. Pediatric brain stem gliomas. Cancer. 1980; 45(11):2787-92. Epub 1980/06/01. PMID: 7379009.
6. Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006; 7(3):241-8. Epub 2006/03/03. doi: 10.1016/S1470-2045(06)70615-5 PMID: 16510333.
7. Freeman CR, Farmer J-P. Pediatric brain stem gliomas: A review. International Journal of Radiation Oncology∗Biology∗Physics. 1998; 40(2):265-71. http://dx.doi.org/10.1016/S0360-3016(97)00572-5. PMID: 9457808
8. Roujeau T, Machado G, Garnett MR, Miquel C, Puget S, Geoerger B, et al. Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg. 2007; 107(1 Suppl):1-4. Epub 2007/07/25. doi: 10.3171/PED-07/07/001 PMID: 17647306.
9. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta neuropathologica. 2012; 124(3):439-47. Epub 2012/06/05. doi: 10.1007/s00401-012-0998-0 PMID: 22661320; PubMed Central PMCID: PMCPmc3422615.
10. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012; 482(7384):226-31. doi: 10.1038/nature10833 PMID: 22286061.
11. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer cell. 2012; 22(4):425-37. doi: 10.1016/j.ccr.2012.08.024 PMID: 23079654.
12. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nature genetics. 2012; 44(3):251-3. doi: 10.1038/ng.1102 PMID: 22286216; PubMed Central PMCID: PMC3288377.
13. Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nature genetics. 2014; 46(5):444-50. doi: 10.1038/ng.2938 PMID: 24705251; PubMed Central PMCID: PMC4056452.
14. Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M, et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature genetics. 2014; 46(5):451-6. doi: 10.1038/ng.2936 PMID: 24705254; PubMed Central PMCID: PMC3997489.
15. Taylor KR, Mackay A, Truffaux N, Butterfield YS, Morozova O, Philippe C, et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nature genetics. 2014; 46(5):457-61. doi: 10.1038/ng.2925 PMID: 24705252; PubMed Central PMCID: PMC4018681.
16. Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO, et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nature genetics. 2014; 46(5):462-6. doi: 10.1038/ng.2950 PMID: 24705250.
17. Lewis PW, Müller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, et al. Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma. Science. 2013; 340(6134):857-61. doi: 10.1126/science.1232245 PMID: 23539183
18. Bender S, Tang Y, Lindroth AM, Hovestadt V, Jones DT, Kool M, et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer cell. 2013; 24(5):660-72. doi: 10.1016/j.ccr.2013.10.006 PMID: 24183680.
19. Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes & development. 2013; 27(9):985-90. doi: 10.1101/gad.217778.113 PMID: 23603901; PubMed Central PMCID: PMC3656328.
20. Grill J, Puget S, Andreiuolo F, Philippe C, MacConaill L, Kieran MW. Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatric blood & cancer. 2012; 58(4):489-91. doi: 10.1002/pbc.24060 PMID: 22190243.
21. Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(30):3999-4006. doi: 10.1200/JCO.2011.35.5677 PMID: 21931021; PubMed Central PMCID: PMC3209696.
22. Puget S, Philippe C, Bax DA, Job B, Varlet P, Junier MP, et al. Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PloS one. 2012; 7(2):e30313. doi: 10.1371/journal.pone.0030313 PMID: 22389665; PubMed Central PMCID: PMC3289615.
23. Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, Huang A, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(8):1337-44. doi: 10.1200/JCO.2009.25.5463 PMID: 20142589.
24. Paugh BS, Zhu X, Qu C, Endersby R, Diaz AK, Zhang J, et al. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Cancer research. 2013; 73(20):6219-29. doi: 10.1158/0008-5472.CAN-13-1491 PMID: 23970477; PubMed Central PMCID: PMC3800209.
25. Albright AL, Packer RJ, Zimmerman R, Rorke LB, Boyett J, Hammond GD. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group. Neurosurgery. 1993; 33(6):1026-9; discussion 9-30. PMID: 8133987.
26. Monje M, Mitra SS, Freret ME, Raveh TB, Kim J, Masek M, et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(11):4453-8. doi: 10.1073/pnas.1101657108 PMID: 21368213; PubMed Central PMCID: PMC3060250.
27. Barton KL, Misuraca K, Cordero F, Dobrikova E, Min HD, Gromeier M, et al. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. PloS one. 2013; 8(10):e77639. doi: 10.1371/journal.pone.0077639 PMID: 24098593; PubMed Central PMCID: PMC3788718.
28. Becher OJ, Hambardzumyan D, Walker TR, Helmy K, Nazarian J, Albrecht S, et al. Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer research. 2010; 70(6):2548-57. doi: 10.1158/0008-5472.CAN-09-2503 PMID: 20197468; PubMed Central PMCID: PMC3831613.
29. Carboni JM, Wittman M, Yang Z, Lee F, Greer A, Hurlburt W, et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Molecular cancer therapeutics. 2009; 8(12):3341-9. doi: 10.1158/1535-7163.MCT-09-0499 PMID: 19996272.
30. Wojtalla A, Salm F, Christiansen DG, Cremona T, Cwiek P, Shalaby T, et al. Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma. PloS one. 2012; 7(10):e47109. doi: 10.1371/journal.pone.0047109 PMID: 23056595; PubMed Central PMCID: PMC3466180.
31. Yin S, Girnita A, Stromberg T, Khan Z, Andersson S, Zheng H, et al. Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro-oncology. 2010; 12(1):19-27. doi: 10.1093/neuonc/nop008 PMID: 20150364; PubMed Central PMCID: PMC2940558.
32. Resnicoff M, Rubini M, Baserga R, Rubin R. Ethanol inhibits insulin-like growth factor-1-mediated signalling and proliferation of C6 rat glioblastoma cells. Laboratory investigation; a journal of technical methods and pathology. 1994; 71(5):657-62. PMID: 7526037.
33. Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, et al. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer research. 1994; 54(8):2218-22. PMID: 8174129.
34. Scotlandi K, Avnet S, Benini S, Manara MC, Serra M, Cerisano V, et al. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. International journal of cancer Journal international du cancer. 2002; 101(1):11-6. doi: 10.1002/ijc.10537 PMID: 12209582.
35. Huang F, Hurlburt W, Greer A, Reeves KA, Hillerman S, Chang H, et al. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer research. 2010; 70(18):7221-31. doi: 10.1158/0008-5472.CAN-10-0391 PMID: 20807811.
36. Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, et al. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatric blood & cancer. 2011; 56(4):595-603. doi: 10.1002/pbc.22741 PMID: 21298745; PubMed Central PMCID: PMC4263954.
37. Buczkowicz P, Zarghooni M, Bartels U, Morrison A, Misuraca KL, Chan T, et al. Aurora kinase B is a potential therapeutic target in pediatric diffuse intrinsic pontine glioma. Brain pathology. 2013; 23(3):244-53. doi: 10.1111/j.1750-3639.2012.00633.x PMID: 22971244.
38. Holland EC, Varmus HE. Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95(3):1218-23. PMID: 9448312; PubMed Central PMCID: PMC18724.
39. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer cell. 2006; 9(5):391-403. http://dx.doi.org/10.1016/j.ccr.2006.03.030. PMID: 16697959
40. Hou X, Huang F, Macedo LF, Harrington SC, Reeves KA, Greer A, et al. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer research. 2011; 71(24):7597-607. doi: 10.1158/0008-5472.CAN-11-1080 PMID: 22042792; PubMed Central PMCID: PMC4004036.
41. Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Molecular cancer therapeutics. 2012; 11(12):2644-53. doi: 10.1158/1535-7163.MCT-12-0447 PMID: 23047891.